These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 27559615)

  • 41. Pharmacological characterization of [³H]CHIBA-3007 binding to glycine transporter 1 in the rat brain.
    Zhang J; Wu J; Toyohara J; Fujita Y; Chen H; Hashimoto K
    PLoS One; 2011; 6(6):e21322. PubMed ID: 21731704
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas.
    Perry KW; Falcone JF; Fell MJ; Ryder JW; Yu H; Love PL; Katner J; Gordon KD; Wade MR; Man T; Nomikos GG; Phebus LA; Cauvin AJ; Johnson KW; Jones CK; Hoffmann BJ; Sandusky GE; Walter MW; Porter WJ; Yang L; Merchant KM; Shannon HE; Svensson KA
    Neuropharmacology; 2008 Oct; 55(5):743-54. PubMed ID: 18602930
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Design, synthesis, and pharmacological evaluation of benzamide derivatives as glucokinase activators.
    Mao W; Ning M; Liu Z; Zhu Q; Leng Y; Zhang A
    Bioorg Med Chem; 2012 May; 20(9):2982-91. PubMed ID: 22459213
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inhibition of glycine transporter 1 attenuates nicotine- but not food-induced cue-potentiated reinstatement for a response previously paired with sucrose.
    Uslaner JM; Drott JT; Sharik SS; Theberge CR; Sur C; Zeng Z; Williams DL; Hutson PH
    Behav Brain Res; 2010 Feb; 207(1):37-43. PubMed ID: 19799936
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Design, synthesis, and evaluation of pyrrolo[2,1-f][1,2,4]triazine derivatives as novel hedgehog signaling pathway inhibitors.
    Xin M; Zhang L; Tang F; Tu C; Wen J; Zhao X; Liu Z; Cheng L; Shen H
    Bioorg Med Chem; 2014 Feb; 22(4):1429-40. PubMed ID: 24486203
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Alterations in the hippocampal glycinergic system in an animal model of posttraumatic stress disorder.
    Yamamoto S; Morinobu S; Iwamoto Y; Ueda Y; Takei S; Fujita Y; Yamawaki S
    J Psychiatr Res; 2010 Nov; 44(15):1069-74. PubMed ID: 20427053
    [TBL] [Abstract][Full Text] [Related]  

  • 47. De Novo Design, Synthesis, and Biological Evaluation of 3,4-Disubstituted Pyrrolidine Sulfonamides as Potent and Selective Glycine Transporter 1 Competitive Inhibitors.
    Wang Y; Zhao H; Brewer JT; Li H; Lao Y; Amberg W; Behl B; Akritopoulou-Zanze I; Dietrich J; Lange UEW; Pohlki F; Hoft C; Hornberger W; Djuric SW; Sydor J; Mezler M; Relo AL; Vasudevan A
    J Med Chem; 2018 Sep; 61(17):7486-7502. PubMed ID: 29969029
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of the glycine reuptake inhibitors bitopertin and RG7118 on glycine in cerebrospinal fluid: results of two proofs of mechanism studies in healthy volunteers.
    Hofmann C; Pizzagalli F; Boetsch C; Alberati D; Ereshefsky L; Jhee S; Patat A; Boutouyrie-Dumont B; Martin-Facklam M
    Psychopharmacology (Berl); 2016 Jul; 233(13):2429-39. PubMed ID: 27178435
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Translational characterization of [11C]GSK931145, a PET ligand for the glycine transporter type 1.
    Gunn RN; Murthy V; Catafau AM; Searle G; Bullich S; Slifstein M; Ouellet D; Zamuner S; Herance R; Salinas C; Pardo-Lozano R; Rabiner EA; Farre M; Laruelle M
    Synapse; 2011 Dec; 65(12):1319-32. PubMed ID: 21688322
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhibitors of Glycine Transporter-1: Potential Therapeutics for the Treatment of CNS Disorders.
    Cioffi CL; Guzzo PR
    Curr Top Med Chem; 2016; 16(29):3404-3437. PubMed ID: 27048272
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Atropisomeric 4-phenyl-4H-1,2,4-triazoles as selective glycine transporter 1 inhibitors.
    Sugane T; Tobe T; Hamaguchi W; Shimada I; Maeno K; Miyata J; Suzuki T; Kimizuka T; Sakamoto S; Tsukamoto S
    J Med Chem; 2013 Jul; 56(14):5744-56. PubMed ID: 23837744
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Blockade of glycine transporter 1 by SSR-504734 promotes cognitive flexibility in glycine/NMDA receptor-dependent manner.
    Nikiforuk A; Kos T; Rafa D; Behl B; Bespalov A; Popik P
    Neuropharmacology; 2011; 61(1-2):262-7. PubMed ID: 21530555
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synthesis and biological evaluation of 3-biphenyl-4-yl-4-phenyl-4H-1,2,4-triazoles as novel glycine transporter 1 inhibitors.
    Sugane T; Tobe T; Hamaguchi W; Shimada I; Maeno K; Miyata J; Suzuki T; Kimizuka T; Kohara A; Morita T; Doihara H; Saita K; Aota M; Furutani M; Shimada Y; Hamada N; Sakamoto S; Tsukamoto S
    J Med Chem; 2011 Jan; 54(1):387-91. PubMed ID: 21141920
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sarcosine preconditioning induces ischemic tolerance against global cerebral ischemia.
    Pinto MC; Simão F; da Costa FL; Rosa DV; de Paiva MJ; Resende RR; Romano-Silva MA; Gomez MV; Gomez RS
    Neuroscience; 2014 Jun; 271():160-9. PubMed ID: 24797328
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Screening for New Inhibitors of Glycine Transporter 1 and 2 by Means of MS Binding Assays.
    Ackermann TM; Höfner G; Wanner KT
    ChemMedChem; 2021 Oct; 16(19):3094-3104. PubMed ID: 34174033
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacological characterisation of the GlyT-1 glycine transporter using two novel radioligands.
    Herdon HJ; Roberts JC; Coulton S; Porter RA
    Neuropharmacology; 2010 Nov; 59(6):558-65. PubMed ID: 20691713
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 1,3-diaminopropan-2-ol sulfonamides as potent and selective inhibitors of the glycine transporter type 1.
    Rahman SS; Coulton S; Herdon HJ; Joiner GF; Jin J; Porter RA
    Bioorg Med Chem Lett; 2007 Mar; 17(6):1741-5. PubMed ID: 17234406
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Glutamate-based therapeutic approaches: inhibitors of glycine transport.
    Lechner SM
    Curr Opin Pharmacol; 2006 Feb; 6(1):75-81. PubMed ID: 16376148
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Discovery of 2-chloro-N-((4,4-difluoro-1-hydroxycyclohexyl)methyl)-5-(5-fluoropyrimidin-2-yl)benzamide as a potent and CNS penetrable P2X7 receptor antagonist.
    Chen X; Pierce B; Naing W; Grapperhaus ML; Phillion DP
    Bioorg Med Chem Lett; 2010 May; 20(10):3107-11. PubMed ID: 20392639
    [TBL] [Abstract][Full Text] [Related]  

  • 60. GlyT-2 mediates the forskolin-induced increase of glycinergic transmission.
    Nakamura M; Jang IS
    Neuroreport; 2010 Apr; 21(6):463-8. PubMed ID: 20335821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.